Market Overview

UPDATE: Stifel Nicolaus Raises PT to $6.51 on Boston Scientific Corporation S-ICD Checks

Share:
Related BSX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Opinion: Here Are 10 Trends (And 11 Investments) To Watch In 2015
Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog (Zacks)

Stifel Nicolaus reiterated Boston Scientific Corporation (NYSE: BSX) at Buy and increased the price target from $6.50 to $7.00.

Stifel Nicolaus noted, "Our recent physician checks with U.S. and EU electrophysiologists (EPs) reinforce our thesis that ultimately S-ICDs could represent 10% or more of overall ICD implants over time, if ongoing registry trials continue to suggest comparable performance versus traditional ICDs. We suspect this 10% penetration is greater than generally expected. These checks also reinforced our view that the S-ICD could potentially help re-invigorate BSX's beleaguered ICD franchise (~19% of 2012 estimated sales)."

Boston Scientific Corporation closed at $6.51 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Jan 2015Leerink SwannUpgradesMarket PerformOutperform
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters